CureLab Oncology

CureLab Oncology is a pioneering biotechnology company focused on developing innovative anti-cancer biologics. With a strong commitment to improving the lives of oncology patients, CureLab Oncology is dedicated to creating revolutionary therapies designed to prolong lives and enhance overall well-being.

Located in Boston, Massachusetts, CureLab Oncology's primary address is Boston, Massachusetts 02138, US. The company's lead product, Elenagen™, is a plasmid encoding gene p62/SQSTM1, which has shown promising results in reversing tumor grade, changing the tumor microenvironment, and stimulating an immune response against tumors. Elenagen™ also enhances the effectiveness of other cancer therapies, such as chemotherapy, and mitigates chronic inflammation.

CureLab Oncology has successfully completed international Phase I/IIa Clinical Trials of Elenagen™, demonstrating a high degree of safety and clinical benefits for patients. Building on these achievements, CureLab Oncology has initiated Phase II Clinical Trials outside the United States and is actively preparing for Phase II Clinical Trials within the US. We invite the manager of CureLab Oncology to create a customized and exclusive company showcase and product listing on our platform.